Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Peginterferon alfa-2a
| Clinical data | |
|---|---|
| Trade names | Pegasys, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a605029 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number |
|
| DrugBank | |
| ChemSpider |
|
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C860H1353N227O255S9 |
| Molar mass | 19241.16 g·mol−1 |
  (what is this?) (verify) | |
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B.[3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%.[3][4] For hepatitis B it may be used alone.[5] It is given by injection under the skin.[3]
Side effects are common.[6] They may include headache, feeling tired, depression, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever.[3] Severe side effects may include psychosis, autoimmune disorders, blood clots, or infections.[3] Use with ribavirin is not recommended during pregnancy.[3] Pegylated interferon alfa-2a is in the alpha interferon family of medications.[3] It is pegylated to protect the molecule from breakdown.[6]
Pegylated interferon alfa-2a was approved for medical use in the United States in 2002.[3] It is on the World Health Organization's List of Essential Medicines.[7]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Pegasys EPAR". European Medicines Agency (EMA). 20 June 2002. Retrieved 5 September 2024.
- ^ a b c d e f g h "Peginterferon Alfa-2a (Professional Patient Advice) - Drugs.com". www.drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017.
- ^ "Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 13 January 2017. Retrieved 12 January 2017.
- ^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 639. ISBN 9780857111562.
- ^ a b "Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. Archived from the original on 23 December 2016. Retrieved 12 January 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Previous Page Next Page
